General MedicationsORALGeneric
CEPHALEXIN
CEPHALEXIN
Standard Dose
EQ 250MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons*
Max Dose
Refer to approved labeling
Primary Use
Marketing status: Discontinued
Key Takeaways
- Primary indication: Marketing status: Discontinued
- Approval overview CEPHALEXIN is listed in Drugs@FDA under application 062117 (ANDA).
- Marketing status: Discontinued Active ingredient CEPHALEXIN Form and strength FOR SUSPENSION;ORAL - EQ 250MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons* Sponsor FACTA FARMA Submission history Latest submission status date: 2000-05-01 00:00:00.
Structured Monograph
Clinical summary
Approval overview CEPHALEXIN is listed in Drugs@FDA under application 062117 (ANDA). Marketing status: Discontinued Active ingredient CEPHALEXIN Form and strength FOR SUSPENSION;ORAL - EQ 250MG BASE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons* Sponsor FACTA FARMA Submission history Latest submission status date: 2000-05-01 00:00:00. Submission type: SUPPL.
Monitoring
- • Review priority: STANDARD
- • Marketing status: Discontinued
Interaction Notes
- No interaction notes stored yet.